Insider buying last 90 days
No open-market insider purchases were filed for UTHR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
United Therapeutics saw record third-quarter 2026 revenue of $833 million, with Tyvaso sales reaching $504 million, though the company pushed back a planned regulatory submission for its soft mist inhaler to 2027. Q3 EPS of $5.71 came in below the $6.01 estimate, and the stock reacted with a -5.9% move around the report. H.C. Wainwright resumed coverage with a Buy rating and a $660.00 price target, while reports also noted operating margins and GAAP profit declined even as revenue topped expectations. Separate filings detailed multiple sales by family trusts linked to Chairperson and CEO Martine A. Rothblatt under a pre-arranged Rule 10b5-1 plan.
UTHR closed at $582.46, up 3.6%, sitting above both its 50-day average of $535.33 and 200-day average of $535.04, with the shorter average above the longer one. The GekkoIndex reads 52.8, placing the stock in the Neutral zone. Gekko Fair Value stands at $676.36, leaving the price 13.9% below that level.
The next earnings date falls on 24 February 2027, 101 days away, outside a typical 20-trading-day holding window. Over the last 30 days, 2 unusual options signals have appeared, with call premium of $4.9 million against put premium of $280,000. Analyst consensus across 14 firms includes 11 buy, 2 hold and 1 sell ratings, with a consensus target of $670.93. Seasonally, the next 20 trading days have averaged a 0.6% gain over 5 years, rising in 3 of them.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
United Therapeutics scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $591.17 is above the 50-day ($542.60) and 200-day ($537.46) averages, and the 50-day is above the 200-day.
See the chart51, Neutral
Reading 51 is in the Neutral zone.
See the GekkoIndex11.2% below
Price is 11.2% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 2 unusual options signals.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings+2.6% on average
From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
United Therapeutics closed at $591.17 on Nov 13, 2026, +28.1% over the past year, inside a 52-week range of $455.63 to $614.23.
Use the left and right arrow keys to read daily values.
Put UTHR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
United Therapeutics is a biotechnology company focused on treatments for people with chronic and severe illnesses, some of them life-threatening. It is best known for a group of therapies used in pulmonary arterial hypertension, including Remodulin, Tyvaso, Orenitram and Adcirca, which work to ease symptoms and improve patients' ability to exercise, along with Unituxin, an antibody-based treatment for high-risk neuroblastoma.
Beyond its marketed products, the company runs a pipeline of experimental treatments and devices, among them Tyvaso DPI, the Remunity Pump, RemoPro, Ralinepag and a gene therapy called Aurora-GT aimed at lung blood vessel regeneration, and it is running trials looking at Tyvaso in patients with a form of pulmonary hypertension tied to COPD. It also works with partners such as DEKA Research & Development, MannKind and Arena Pharmaceuticals on delivery devices and drug development, and its business reaches patients in both the United States and other countries.
United Therapeutics was founded in 1996 and is headquartered in Silver Spring, Maryland. Its shares are listed on the NASDAQ under the ticker UTHR.
United Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51, in the Neutral zone, down 3.4 points over five sessions.
Down 3.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 11 | +3.0% | +4.7% | ||
| Accumulation | 199 | +0.9% | +1.9% | ||
| Neutral (current zone) | 448 | +0.9% | +4.0% | ||
| Distribution | 42 | −1.2% | +1.8% | ||
| Selling | 2 | Too few readings yet | |||
Average UTHR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
United Therapeutics trades 11.2% below Gekko Fair Value of $665.56, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what United Therapeutics shares are worth, recalculated every trading day.
$665.56
Gekko Fair Value, Nov 14, 2026
11.2% Undervalued
At the end of Aug 2026 the price was 24.6% below the estimate.
No open-market insider purchases were filed for United Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for UTHR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in UTHR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
United Therapeutics has been buying back its own shares.
From company filings.
2signals, 95% of the flagged premium in calls.
Latest: Bullish flow on Nov 4, $829K in unusual premium.
1of the funds Gekko tracks holds UTHR.
United Therapeutics reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 24, 2027
Expected before the open, 101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $5.71 est $6.01 | $832.5M est $781.1M | −5.9% |
| Aug 5, 2026 | $7.27 est $6.82 | $783.3M est $804.6M | +2.7% |
| May 6, 2026 | $5.82 est $6.86 | $781.5M est $797.4M | −0.5% |
| Feb 25, 2026 | $7.70 est $7.13 | $790.2M est $813.1M | +6.4% |
| Oct 29, 2025 | $7.16 est $6.89 | $799.5M est $814.8M | +9.2% |
| Jul 30, 2025 | $6.41 est $6.94 | $798.6M est $801.9M | −7.7% |
| Apr 30, 2025 | $6.63 est $6.28 | $794.4M est $778.7M | −2.3% |
| Feb 26, 2025 | $6.19 est $6.27 | $735.9M est $734.7M | −9.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for United Therapeutics is $687.14, +16.2% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | H.C. Wainwright | $660 | +11.6% |
| Nov 5 | TD Cowen | $700 | +18.4% |
| Nov 5 | Leerink Partners | $725 | +22.6% |
| Nov 5 | Wells Fargo | $703 | +18.9% |
| Nov 5 | Morgan Stanley | $568 | −3.9% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, United Therapeutics averaged +2.6% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 3 of 5 |
| Next 10 trading days | −0.4% | 3 of 5 |
| Next 15 trading days | +0.6% | 3 of 5 |
| Next 20 trading days | +2.6% | 3 of 5 |
| Next 30 trading days | +0.9% | 3 of 5 |
For scale, UTHR’s typical 20-trading-day move in either direction is about 5.3%.
United Therapeutics’s market cap is $25.18B, with a P/E ratio of 22.4 and revenue of $3.19B over the last twelve months.
Coverage of United Therapeutics this week reads neutral: 3 positive, 10 neutral and 5 negative headlines.
United Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| NBIXNeurocrine Biosciences | Neutral | 28.9% below |
A peer links to its own page where one exists.
United Therapeutics’s market cap is $25.18B at the Nov 13, 2026 close of $591.17, with 42.59M shares outstanding. The shares trade on a P/E ratio of 22.4.
The consensus analyst 12-month price target for United Therapeutics is $687.14, +16.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 11 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate United Therapeutics is undervalued: the Nov 13, 2026 close of $591.17 is 11.2% below Gekko Fair Value of $665.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
United Therapeutics is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of $4.95 per share on revenue of $861.6M. United Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 5.5% on average across the report.
United Therapeutics’s 52-week high is $614.23 and its 52-week low is $455.63; it closed at $591.17 on Nov 13, 2026, +28.1% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in United Therapeutics over the last 30 days, with $4.90M of flagged premium in calls and $280K in puts. The latest, bullish flow, was on Nov 4, 2026 with $829K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.